Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies targeting the complement system to treat diseases with high unmet needs. Its core products include pegcetacoplan-based treatments SYFOVRE for geographic atrophy in age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria. Apellis serves patients in ophthalmology and rare diseases, leveraging proprietary complement inhibition technology and collaborations for global commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.